Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells

Cancer Letters

Volumn 357, Issue 2, 2015, Pages 591-601

  Choi, Minji ^a   Kim, Wootae ^a   Cheon, Min Gyeong ^a   Lee, Chang Woo ^b   Kim, Ja Eun ^a  

^a Kyung Hee University Hospital   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

BI2536; Mitosis; Mitotic catastrophe; Non small cell lung cancer; PLK1; Spindle assembly checkpoint

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; NOCODAZOLE; POLO LIKE KINASE 1; ANTIMITOTIC AGENT; CELL CYCLE PROTEIN; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE; PTERIDINE DERIVATIVE;

A427 CELL LINE; A549 CELL LINE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CENTROMERE; CENTROSOME; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LUNG CANCER CELL LINE; M PHASE CELL CYCLE CHECKPOINT; MICROSCOPY; MITOSIS INHIBITION; MITOSIS SPINDLE; MITOTIC CATASTROPHE; NCI H1299 CELL LINE; NON SMALL CELL LUNG CANCER; TIME LAPSE IMAGING; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; FLUORESCENCE MICROSCOPY; LUNG TUMOR; METABOLISM; MITOSIS; PATHOLOGY; SPINDLE APPARATUS; TUMOR CELL LINE;

ANTIMITOTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LUNG NEOPLASMS; M PHASE CELL CYCLE CHECKPOINTS; MICROSCOPY, FLUORESCENCE; MITOSIS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PTERIDINES; SPINDLE APPARATUS; TIME-LAPSE IMAGING;

EID: 84920747012     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.12.023     Document Type: Article

References (72)

1. Pines J. Mitosis: a matter of getting rid of the right protein at the right time. Trends Cell Biol 2006, 16:55-63.
2. Kops G.J., Weaver B.A., Cleveland D.W. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat. Rev. Cancer 2005, 5:773-785.
3. Schvartzman J.M., Sotillo R., Benezra R. Mitotic chromosomal instability and cancer: mouse modelling of the human disease. Nat. Rev. Cancer 2010, 10:102-115.
4. Holland A.J., Cleveland D.W. Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis. Nat. Rev. Mol. Cell Biol 2009, 10:478-487.
5. Chin C.F., Yeong F.M. Safeguarding entry into mitosis: the antephase checkpoint. Mol. Cell Biol 2010, 30:22-32.
6. Musacchio A., Salmon E.D. The spindle-assembly checkpoint in space and time. Nat. Rev. Mol. Cell Biol 2007, 8:379-393.
7. Lara-Gonzalez P., Westhorpe F.G., Taylor S.S. The spindle assembly checkpoint. Curr. Biol 2012, 22:R966-R980.
8. Foley E.A., Kapoor T.M. Microtubule attachment and spindle assembly checkpoint signalling at the kinetochore. Nat. Rev. Mol. Cell Biol 2013, 14:25-37.
9. Agromayor M., Martin-Serrano J. Knowing when to cut and run: mechanisms that control cytokinetic abscission. Trends Cell Biol 2013, 23:433-441.
10. Malumbres M., Barbacid M. Cell cycle kinases in cancer. Curr. Opin. Genet. Dev 2007, 17:60-65.
11. Li J.J., Li S.A. Mitotic kinases: the key to duplication, segregation, and cytokinesis errors, chromosomal instability, and oncogenesis. Pharmacol. Ther 2006, 111:974-984.
12. Barr F.A., Sillje H.H., Nigg E.A. Polo-like kinases and the orchestration of cell division. Nat. Rev. Mol. Cell Biol 2004, 5:429-440.
13. Archambault V., Glover D.M. Polo-like kinases: conservation and divergence in their functions and regulation. Nat. Rev. Mol. Cell Biol 2009, 10:265-275.
14. van de Weerdt B.C., Medema R.H. Polo-like kinases: a team in control of the division. Cell Cycle 2006, 5:853-864.
15. Golsteyn R.M., Mundt K.E., Fry A.M., Nigg E.A. Cell cycle regulation of the activity and subcellular localization of Plk1, a human protein kinase implicated in mitotic spindle function. J. Cell Biol 1995, 129:1617-1628.
16. Golsteyn R.M., Schultz S.J., Bartek J., Ziemiecki A., Ried T., Nigg E.A. Cell cycle analysis and chromosomal localization of human Plk1, a putative homologue of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5. J. Cell Sci 1994, 107(Pt 6):1509-1517.
17. Kishi K., van Vugt M.A., Okamoto K., Hayashi Y., Yaffe M.B. Functional dynamics of Polo-like kinase 1 at the centrosome. Mol. Cell. Biol 2009, 29:3134-3150.
18. Petronczki M., Lenart P., Peters J.M. Polo on the rise-from mitotic entry to cytokinesis with Plk1. Dev. Cell 2008, 14:646-659.
19. Mundt K.E., Golsteyn R.M., Lane H.A., Nigg E.A. On the regulation and function of human polo-like kinase 1 (PLK1): effects of overexpression on cell cycle progression. Biochem. Biophys. Res. Commun 1997, 239:377-385.
20. Sumara I., Gimenez-Abian J.F., Gerlich D., Hirota T., Kraft C., de la Torre C., et al. Roles of polo-like kinase 1 in the assembly of functional mitotic spindles. Curr. Biol 2004, 14:1712-1722.
21. Ahonen L.J., Kallio M.J., Daum J.R., Bolton M., Manke I.A., Yaffe M.B., et al. Polo-like kinase 1 creates the tension-sensing 3F3/2 phosphoepitope and modulates the association of spindle-checkpoint proteins at kinetochores. Curr. Biol 2005, 15:1078-1089.
22. Elowe S., Hummer S., Uldschmid A., Li X., Nigg E.A. Tension-sensitive Plk1 phosphorylation on BubR1 regulates the stability of kinetochore microtubule interactions. Genes Dev 2007, 21:2205-2219.
23. Takai N., Hamanaka R., Yoshimatsu J., Miyakawa I. Polo-like kinases (Plks) and cancer. Oncogene 2005, 24:287-291.
24. Chopra P., Sethi G., Dastidar S.G., Ray A. Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics. Expert Opin. Investig. Drugs 2010, 19:27-43.
25. Strebhardt K., Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat. Rev. Cancer 2006, 6:321-330.
26. Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat. Rev. Drug Discov 2010, 9:643-660.
27. Degenhardt Y., Lampkin T. Targeting Polo-like kinase in cancer therapy. Clin. Cancer Res 2010, 16:384-389.
28. Yim H. Current clinical trials with polo-like kinase 1 inhibitors in solid tumors. Anticancer Drugs 2013, 24:999-1006.
29. Schoffski P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 2009, 14:559-570.
30. Lenart P., Petronczki M., Steegmaier M., Di Fiore B., Lipp J.J., Hoffmann M., et al. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr. Biol 2007, 17:304-315.
31. Steegmaier M., Hoffmann M., Baum A., Lenart P., Petronczki M., Krssak M., et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr. Biol 2007, 17:316-322.
32. Sanhaji M., Kreis N.N., Zimmer B., Berg T., Louwen F., Yuan J. p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors. Cell Cycle 2012, 11:543-553.
33. Sebastian M., Reck M., Waller C.F., Kortsik C., Frickhofen N., Schuler M., et al. The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial. J. Thorac. Oncol 2010, 5:1060-1067.
34. Ellis P.M., Chu Q.S., Leighl N., Laurie S.A., Fritsch H., Gaschler-Markefski B., et al. A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer. Clin. Lung Cancer 2013, 14:19-27.
35. Yasui Y., Urano T., Kawajiri A., Nagata K., Tatsuka M., Saya H., et al. Autophosphorylation of a newly identified site of Aurora-B is indispensable for cytokinesis. J. Biol. Chem 2004, 279:12997-13003.
36. Macurek L., Lindqvist A., Lim D., Lampson M.A., Klompmaker R., Freire R., et al. Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature 2008, 455:119-123.
37. Carmena M., Pinson X., Platani M., Salloum Z., Xu Z., Clark A., et al. The chromosomal passenger complex activates Polo kinase at centromeres. PLoS Biol 2012, 10:e1001250.
38. Elowe S., Dulla K., Uldschmid A., Li X., Dou Z., Nigg E.A. Uncoupling of the spindle-checkpoint and chromosome-congression functions of BubR1. J. Cell Sci 2010, 123:84-94.
39. Huang H., Hittle J., Zappacosta F., Annan R.S., Hershko A., Yen T.J. Phosphorylation sites in BubR1 that regulate kinetochore attachment, tension, and mitotic exit. J. Cell Biol 2008, 183:667-680.
40. Matsumura S., Toyoshima F., Nishida E. Polo-like kinase 1 facilitates chromosome alignment during prometaphase through BubR1. J. Biol. Chem 2007, 282:15217-15227.
41. Fang G. Checkpoint protein BubR1 acts synergistically with Mad2 to inhibit anaphase-promoting complex. Mol. Biol. Cell 2002, 13:755-766.
42. Han J.S., Holland A.J., Fachinetti D., Kulukian A., Cetin B., Cleveland D.W. Catalytic assembly of the mitotic checkpoint inhibitor BubR1-Cdc20 by a Mad2-induced functional switch in Cdc20. Mol. Cell 2013, 51:92-104.
43. Tang Z., Bharadwaj R., Li B., Yu H. Mad2-Independent inhibition of APCCdc20 by the mitotic checkpoint protein BubR1. Dev. Cell 2001, 1:227-237.
44. Orr B., Bousbaa H., Sunkel C.E. Mad2-independent spindle assembly checkpoint activation and controlled metaphase-anaphase transition in Drosophila S2 cells. Mol. Biol. Cell 2007, 18:850-863.
45. Li D., Morley G., Whitaker M., Huang J.Y. Recruitment of Cdc20 to the kinetochore requires BubR1 but not Mad2 in Drosophila melanogaster. Mol. Cell. Biol 2010, 30:3384-3395.
46. Chin G.M., Herbst R. Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint. Mol. Cancer Ther 2006, 5:2580-2591.
47. Dick A.E., Gerlich D.W. Kinetic framework of spindle assembly checkpoint signalling. Nat. Cell Biol 2013, 15:1370-1377.
48. Jang Y.J., Ma S., Terada Y., Erikson R.L. Phosphorylation of threonine 210 and the role of serine 137 in the regulation of mammalian polo-like kinase. J. Biol. Chem 2002, 277:44115-44120.
49. Kothe M., Kohls D., Low S., Coli R., Rennie G.R., Feru F., et al. Selectivity-determining residues in Plk1. Chem. Biol. Drug Design 2007, 70:540-546.
50. Burkard M.E., Santamaria A., Jallepalli P.V. Enabling and disabling polo-like kinase 1 inhibition through chemical genetics. ACS Chem. Biol 2012, 7:978-981.
51. Suijkerbuijk S.J., Vleugel M., Teixeira A., Kops G.J. Integration of kinase and phosphatase activities by BUBR1 ensures formation of stable kinetochore-microtubule attachments. Dev. Cell 2012, 23:745-755.
52. Haren L., Stearns T., Luders J. Plk1-dependent recruitment of gamma-tubulin complexes to mitotic centrosomes involves multiple PCM components. PLoS ONE 2009, 4:e5976.
53. Santamaria A., Neef R., Eberspacher U., Eis K., Husemann M., Mumberg D., et al. Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis. Mol. Biol. Cell 2007, 18:4024-4036.
54. Bruinsma W., Macurek L., Freire R., Lindqvist A., Medema R.H. Bora and Aurora-A continue to activate Plk1 in mitosis. J. Cell Sci 2014, 127:801-811.
55. Liu X.S., Song B., Tang J., Liu W., Kuang S., Liu X. Plk1 phosphorylates Sgt1 at the kinetochores to promote timely kinetochore-microtubule attachment. Mol. Cell. Biol 2012, 32:4053-4067.
56. Kang Y.H., Park J.E., Yu L.R., Soung N.K., Yun S.M., Bang J.K., et al. Self-regulated Plk1 recruitment to kinetochores by the Plk1-PBIP1 interaction is critical for proper chromosome segregation. Mol. Cell 2006, 24:409-422.
57. Wong O.K., Fang G. Cdk1 phosphorylation of BubR1 controls spindle checkpoint arrest and Plk1-mediated formation of the 3F3/2 epitope. J. Cell Biol 2007, 179:611-617.
58. Huang H., Yen T.J. BubR1 is an effector of multiple mitotic kinases that specifies kinetochore: microtubule attachments and checkpoint. Cell Cycle 2009, 8:1164-1167.
59. Luo J., Emanuele M.J., Li D., Creighton C.J., Schlabach M.R., Westbrook T.F., et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009, 137:835-848.
60. Yim H., Erikson R.L. Plk1-targeted therapies in TP53- or RAS-mutated cancer. Mutat. Res. Rev. Mutat. Res 2014, 761:31-39.
61. Wolf G., Elez R., Doermer A., Holtrich U., Ackermann H., Stutte H.J., et al. Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 1997, 14:543-549.
62. Liu J., Lu K.H., Liu Z.L., Sun M., De W., Wang Z.X. MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1. BMC Cancer 2012, 12:519.
63. Wang Z.X., Xue D., Liu Z.L., Lu B.B., Bian H.B., Pan X., et al. Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer. Int. J. Biochem. Cell Biol 2012, 44:200-210.
64. Kawata E., Ashihara E., Kimura S., Takenaka K., Sato K., Tanaka R., et al. Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer. Mol. Cancer Ther 2008, 7:2904-2912.
65. Spankuch-Schmitt B., Wolf G., Solbach C., Loibl S., Knecht R., Stegmuller M., et al. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene 2002, 21:3162-3171.
66. Zhao X.Y., Nie C.L., Liang S.F., Yuan Z., Deng H.X., Wei Y.Q. Enhanced gemcitabine-mediated cell killing of human lung adenocarcinoma by vector-based RNA interference against PLK1. Biomedic. Pharmacother 2012, 66:597-602.
67. Spankuch-Schmitt B., Bereiter-Hahn J., Kaufmann M., Strebhardt K. Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J. Natl. Cancer Inst 2002, 94:1863-1877.
68. Spankuch B., Matthess Y., Knecht R., Zimmer B., Kaufmann M., Strebhardt K. Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J. Natl. Cancer Inst 2004, 96:862-872.
69. Kawata E., Ashihara E., Maekawa T. RNA interference against polo-like kinase-1 in advanced non-small cell lung cancers. J. Clin. Bioinformatics 2011, 1:6.
70. Medema R.H., Lin C.C., Yang J.C. Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC. Clin. Cancer Res 2011, 17:6459-6466.
71. Kroemer G., Galluzzi L., Vandenabeele P., Abrams J., Alnemri E.S., Baehrecke E.H., et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 2009, 16:3-11.
72. Vitale I., Galluzzi L., Castedo M., Kroemer G. Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat. Rev. Mol. Cell Biol 2011, 12:385-392.